Paratek is currently carrying out a Phase IIb clinical trial of Nuzyra for nontuberculous mycobacterial pulmonary disease. Credit: fizkes/Shutterstock.com.

Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise.

In June 2023, Novo Holdings announced the signing of a definitive agreement to acquire Paratek.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.

A lead product of the company, Nuzyra (omadacycline), is currently available in the US as a once-a-day oral and intravenous antibiotic.

The treatment is indicated for use in adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). 

See Also:

Paratek is currently carrying out a Phase IIb clinical trial of Nuzyra for nontuberculous mycobacterial (NTM) pulmonary disease. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company also has a partnership agreement in place with Zai Lab for omadacycline’s development and marketing in greater China and retains all worldwide rights for ex-greater China markets.

Novo Holdings partner Aleks Engel said: “We are committed to maintaining Paratek’s leadership in reaching patients and delivering innovative products across the globe. 

“We look forward to supporting the continued growth of Nuzyra, and the expansion of Paratek’s product portfolio, including the acquisition or licensing of other therapeutics in antibiotics and beyond.” 

Novo Holdings is a holding and investment company that manages Novo Nordisk Foundation and healthcare investment firm Gurnet Point’s assets and wealth.